Compare · CRL vs NRC
CRL vs NRC
Side-by-side comparison of Charles River Laboratories International Inc. (CRL) and NRC Health (NRC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CRL and NRC operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- CRL is the larger of the two at $10.91B, about 23.0x NRC ($474.2M).
- Over the past year, CRL is up 26.6% and NRC is up 51.2% - NRC leads by 24.6 points.
- CRL has hit the wire 3 times in the past 4 weeks while NRC has been quiet.
- CRL has more recent analyst coverage (25 ratings vs 1 for NRC).
- Company
- Charles River Laboratories International Inc.
- NRC Health
- Price
- $226.76-1.11%
- $21.03+0.81%
- Market cap
- $10.91B
- $474.2M
- 1M return
- +12.16%
- +2.24%
- 1Y return
- +26.61%
- +51.19%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NYSE
- NASDAQ
- IPO
- 2000
- News (4w)
- 3
- 0
- Recent ratings
- 25
- 1
Charles River Laboratories International Inc.
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains and purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets and chemical compounds through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company was founded in 1947 and is based in Wilmington, Massachusetts.
NRC Health
National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience in the United States and Canada. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, health risk assessments, employee engagement, reputation management, and brand loyalty. The company also offers market insights solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient and resident experience, workforce engagement, health risk assessments, transitions, and improvement tools. Further, the company offers health risk assessment solutions that enable clients to segment populations and manage care for those who are most at risk, engage individuals, enhance preventative care, and manage wellness programs; and transitions solutions, which enable organizations to identify and manage high-risk patients to reduce readmissions, enhance patient satisfaction and support safe care transitions. Additionally, it provides transparency solutions that allow healthcare organizations to share picture of their organization and ensure content informs in consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. The company serves integrated health systems, post-acute providers, and payer organizations. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.
Latest CRL
- Charles River downgraded by CLSA with a new price target
- Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call
- Charles River Provides NGS Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches
- Director Foster James C sold $16,875,000 worth of shares (75,000 units at $225.00) as part of a pre-agreed trading plan, decreasing direct ownership by 70% to 31,596 units (SEC Form 4)
- Charles River Joins Lilly TuneLab to Optimize AI/ML Platform through Nonclinical Testing Expertise
- Charles River upgraded by Morgan Stanley with a new price target
- Director Foster James C gifted 183,361 shares and received a gift of 183,361 shares, decreasing direct ownership by 62% to 106,596 units (SEC Form 4)
- Chief Executive Officer Girshick Birgit gifted 3,386 shares and received a gift of 3,386 shares, decreasing direct ownership by 9% to 36,013 units (SEC Form 4)
- CEVP, Disc & Safety Assessment Parisotto Shannon M gifted 1,529 shares and received a gift of 1,529 shares, decreasing direct ownership by 13% to 9,853 units (SEC Form 4)
- Director Barg Steven was granted 422 shares, increasing direct ownership by 15% to 3,287 units (SEC Form 4)
Latest NRC
- NRC Health filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Berwick Donald M was granted 7,697 shares (SEC Form 4)
- Director Bhandari Parul was granted 7,697 shares (SEC Form 4)
- Director Lockhart Stephen H was granted 7,697 shares (SEC Form 4)
- Director Nunnelly John N was granted 7,697 shares, increasing direct ownership by 24% to 40,363 units (SEC Form 4)
- Director Wheeler Penny Ann was granted 7,697 shares (SEC Form 4)
- Citizens initiated coverage on National Research Corporation with a new price target
- NRC Health and Healthcare Experience Foundation Launch Strategic Partnership to Deepen Support for Improving Experience, Safety, and Workforce Engagement
- The Governance Institute Announces Blue Ribbon Committee on Health System Governance
- NRC Health Brings Ambient Listening With Agentic AI to the Front Lines of Leader Rounding